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Previewswonder whether these effects are truly
restricted to neuroblastomas with MYCN
amplification, as surmised, or might oper-
ate similarly through MYC when this
homolog is deregulated. In high-risk
neuroblastomas that lack MYCN amplifi-
cation, MYC is frequently deregulated
(Westermann et al., 2008), suggesting
some degree of MYC or MYCN augmen-
tation may be essential for the high-risk
phenotype. This was not directly tested
because the available transgenic model
for this tumor mimicsMYCN amplification
as an oncogenic driver and no MYCN
non-amplified tumor xenografts were
explored. Though elucidation of a novel
MYCN-directed therapeutic is significant
enough, the impact may be further broad-
ened to a greater proportion of patients
with high-risk neuroblastoma should
MYC serve a similar role, which is aworthypursuit, and may extend the relevance of
these findings to all human cancers that
usurp MYC signaling as an essential
component of sustaining the malignant
phenotype.
REFERENCES
Baudino, T.A., McKay, C., Pendeville-Samain, H.,
Nilsson, J.A., Maclean, K.H., White, E.L., Davis,
A.C., Ihle, J.N., and Cleveland, J.L. (2002). Genes
Dev. 16, 2530–2543.
Brodeur, G.M., Seeger, R.C., Schwab, M., Varmus,
H.E., and Bishop, J.M. (1984). Science 224, 1121–
1124.
Chanthery, Y.H., Gustafson, W.C., Itsara, M.,
Persson, A., Hackett, C.S., Grimmer, M., Charron,
E., Yakovenko, S., Kim, G., Matthay, K.K., and
Weiss, W.A. (2012). Sci Transl Med. 4, 115ra113.
Chesler, L., Schlieve, C., Goldenberg, D.D.,
Kenney, A., Kim, G., McMillan, A., Matthay, K.K.,
Rowitch, D., and Weiss, W.A. (2006). Cancer Res.
66, 8139–8146.Cancer Cell 21,Delmore, J.E., Issa, G.C., Lemieux, M.E., Rahl,
P.B., Shi, J., Jacobs, H.M., Kastritis, E., Gilpatrick,
T., Paranal, R.M., Qi, J., et al. (2011). Cell 146,
904–917.
Mosse´, Y.P., Laudenslager, M., Longo, L., Cole,
K.A., Wood, A., Attiyeh, E.F., Laquaglia, M.J.,
Sennett, R., Lynch, J.E., Perri, P., et al. (2008).
Nature 455, 930–935.
Soucek, L., Whitfield, J., Martins, C.P., Finch, A.J.,
Murphy, D.J., Sodir, N.M., Karnezis, A.N., Swigart,
L.B., Nasi, S., and Evan, G.I. (2008). Nature 455,
679–683.
Weiss, W.A., Aldape, K., Mohapatra, G., Feuer-
stein, B.G., and Bishop, J.M. (1997). EMBO J. 16,
2985–2995.
Westermann, F., Muth, D., Benner, A., Bauer, T.,
Henrich, K.O., Oberthuer, A., Brors, B., Beissbarth,
T., Vandesompele, J., Pattyn, F., et al. (2008).
Genome Biol. 9, R150.
Yu, A.L., Gilman, A.L., Ozkaynak, M.F., London,
W.B., Kreissman, S.G., Chen, H.X., Smith, M.,
Anderson, B., Villablanca, J.G., Matthay, K.K.,
et al; Children’s Oncology Group. (2010). N. Engl.
J. Med. 363, 1324–1334.The RAF Inhibitor Paradox RevisitedAdrienne D. Cox1,2,* and Channing J. Der1,*
1Department of Radiation Oncology
2Department of Pharmacology
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
*Correspondence: adricox@med.unc.edu (A.D.C.), cjder@med.unc.edu (C.J.D.)
DOI 10.1016/j.ccr.2012.01.017
The success of theRAFprotein kinase inhibitor vemurafenib for the treatment ofBRAFmutantmetastaticmela-
noma has produced another poster child for the promise of personalized medicine. However, the results of
a recent study also reveal unexpected pitfalls in the application of signal transduction-targeted therapies.The era of personalized cancer medicine
is upon us. The cancer patient’s genome
can now be interrogated for specific
genetic alterations to guide the applica-
tion of therapies specifically targeted to
those alterations. A dramatic therapeutic
advance in this area is the BRAF-selective
inhibitor vemurafenib, which has pro-
vided a significant improvement in overall
survival compared to the previous stan-
dard of care for metastatic melanoma
(Chapman et al., 2011). However, recent
findings with vemurafenib and other pro-
tein kinase inhibitors demonstrate that
the new era of signal transduction-tar-
geted therapies is handicapped by some
of the same issues that have plagued
traditional cytotoxic drugs.One key distinction between targeted
versus cytotoxic therapies is decreased
normal cell toxicity. Symptoms such as
the classic myelosuppression associated
with many cytotoxic antineoplastics are
not as limiting with targeted agents,
whose therapeutic effects are typically
achievable at doses lower than those
conferring myelosuppression or other
dose-limiting toxicities. However, rapidly
acquired cancer cell resistance shortens
the duration of treatment response. For
example, although the initial response
to vemurafenib is impressive, with a re-
sponse rate of 50% and significant sur-
vival benefit, tumor resistance usually
occurs within 2–18 months of initial treat-
ment. Multiple mechanisms of resistancehave been described, including muta-
tional activation of NRAS or receptor tyro-
sine kinase-mediated activation of RAS,
both leading to CRAF-dependent activa-
tion of MEK-ERK signaling (Figure 1)
(Johannessen et al., 2010; Nazarian et al.,
2010). Thus, as for cytotoxic drugs, com-
binations of targeted therapies will be
needed, both to enhance the initial re-
sponse and to reduce the subsequent
onset of drug resistance. Such com-
binations may also have advantages in
blocking the existing tumor without
inducing or allowing new ones to appear.
That chemotherapy can both cure and
cause cancer is not a new concept. Con-
ventional cytotoxic chemotherapy has
long been known to contribute to theFebruary 14, 2012 ª2012 Elsevier Inc. 147
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Figure 1. Consequences of RAF Inhibitor Therapy
Cellular responses to vemurafenib treatment in BRAF mutant melanoma or RAS mutant skin epithelial
cells. In both settings, concurrent treatment with a MEK inhibitor may decrease the onset of these mech-
anisms of tumor resistance or tumor progression.
(A) Resistance mechanisms for BRAF mutant melanomas. Inactivation of BRAF (V600E) mutant by RAF
inhibitor initially leads to inhibition of MEK-ERK signaling. However, tumor cells can develop resistance
by multiple mechanisms, including upregulated expression of receptor tyrosine kinases (RTK) or muta-
tional activation of NRAS leading to CRAF-dependent activation of MEK or by overexpression of the
COT/TPL2 serine/threonine protein kinase, a direct activator of MEK1/2.
(B) Mutationally activated RAS forms a complex with a BRAF/CRAF heterodimer. RAF inhibitor binds pref-
erentially to BRAF and inactivates it but also causes transactivation of the associated CRAF, enhancing
MEK-ERK activation and cellular proliferation.
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Previewsdevelopment of secondary cancers that
can arise a decade or more after comple-
tion of successful therapy. These cancers
reflect the inherent DNA damaging and
carcinogenic properties of standard cyto-
toxics. Now, Su et al. (2012) describe
an unexpected consequence of vemura-
fenib therapy: accelerated and enhanced
occurrence of skin tumors. A side effect
of vemurafenib treatment is the rapid
appearance of well-differentiated cuta-
neous squamous cell carcinomas (SCC)
and keratoacanthomas in approximately
15%–30% of melanoma patients. Taking
cues from previous experimental studies
in animal models of carcinogenesis, Su
et al. (2012) asked whether activated
mutants of RAS genes might be associ-
ated with these tumors. In the classical
two-stage carcinogenesis mouse model,
a single treatment with the carcinogen
7,12-dimethylbenz[a]anthracene (DMBA),
followed by multiple treatments with the
tumor promoter 12-O-tetradecanoylphor-
bol-13-acetate (TPA), causes formation
of squamous-cell skin lesions, some of
which progress to malignant carcinomas.
In these carcinomas, there is a high inci-
dence of HRAS mutational activation,
characteristically at codon 61 encoding148 Cancer Cell 21, February 14, 2012 ª2012glutamate (Q61) (Balmain et al., 1984).
Similarly, repeated DMBA treatment of
rabbits causes formation of keratoacan-
thomas with HRAS Q61 mutations (Leon
et al., 1988). Spontaneously occurring
human skin tumors have also been re-
ported to harbor HRAS mutants (Ober-
holzer et al., 2012).
Su et al. (2012) analyzed 35 cutaneous
SCC or keratoacanthomas arising in a
total of 23 vemurafenib-treated mela-
noma patients and identified RAS muta-
tions in 60% of them: 16 harbored HRAS
mutations (2 at G12, 2 at G13, and 12
at Q61), 1 harbored NRAS G12, and 4
harbored KRAS G12 mutations. Similarly,
Oberholzer et al. (2012) found a 30%
frequency of HRASmutation in 10 tumors
from vemurafenib-treated patients, com-
pared with a 3% frequency in spontane-
ously occurring skin tumors.
Recent cell culture and mouse studies
have revealed the ability of RAF-selective
inhibitors both to efficiently block ERK
activation and growth in BRAF(V600E)
mutant, RAS-wild-type melanomas. In
contrast, RAF inhibitors caused a para-
doxical activation, rather than inactiva-
tion, of ERK signaling in BRAF-wild-type,
RASmutant cancer cells (Figure 1) (Hatzi-Elsevier Inc.vassiliou et al., 2010; Heidorn et al., 2010;
Poulikakos et al., 2010). In the latter cells,
the persistently GTP-bound RAS asso-
ciates with BRAF/CRAF heterodimers.
Vemurafenib binding to the wild-type
BRAF inhibits BRAF but causes transacti-
vation of CRAF, leading to MEK and ERK
activation rather than inhibition. Using
high levels of RAF inhibitor that block
both BRAF and CRAF or alternatively
usingMEK inhibitors to block downstream
of RAF could prevent this paradoxical
activation of the pathway. Su et al. (2012)
hypothesized that the same paradoxical
action mechanism originally modeled in
cell culture also occurred in the patient
and used cell culture and mouse model
studies to test this hypothesis.
One particularly compelling analysis
applied vemurafenib in the DMBA/TPA
carcinogenesis mouse model. Control
DMBA/TPA-treated mice developed skin
tumors at the expected rate, whereas
concurrent treatment with vemurafenib
accelerated the time of onset (Su et al.,
2012). Vemurafenib treatment did not in-
crease the frequency of skin lesions, nor
was treatment with DMBA and vemurafe-
nib sufficient to induce skin tumors in
the absence of TPA. Thus, vemurafenib
does not appear to act as a cancer-
causing agent. The RAF inhibitor neither
promoted RAS mutation nor replaced
TPA to function as a tumor promoter,
but it simply accelerated the progression
of already existing, but subclinical, mutant
RAS-containing lesions. This conclusion
is consistent with the clinical observation
that the median onset of skin lesions
was 10 weeks after initiation of treat-
ment. In addition, combination treatment
with both vemurafenib and a selective
MEK1/2 inhibitor in DMBA/TPA-treated
mice resulted in a 91% reduction in tumor
formation, supporting the authors’ main
take-home message that the combined
use of RAF and MEK inhibitors may
prevent the accelerated appearance of
cutaneous squamous-cell carcinomas or
keratoacanthomas in patients treated for
other cancers.
Well-differentiated skin lesions are
easily identified, simple to remove surgi-
cally, and not metastatic. However, their
appearance does raise a significant con-
cern that tumors below the skin, and
thus not so evident, may also be acceler-
ated. Although the predominant RAS
mutation seen in theaccelerated lesionsof
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wasHRASQ61, other mutations detected
included HRAS G12, HRAS G13, NRAS
G12, and KRAS G12 (Su et al., 2012).
Thus, the paradoxical mechanism is not
restricted to HRAS or to a particular acti-
vating mutation. Mutations in KRAS are
very early events in colorectal and pan-
creatic cancers, where mutant KRAS
can be found even in histologically normal
tissue. Would long-term RAF inhibitor
treatment in the adjuvant setting also
accelerate progression of these cancers?
Vemurafenib treatment of mutant KRAS-
driven mouse models of colorectal and
pancreatic cancers would provide a crit-
ical assessment of this possibility.
Finally, one impressive success in ad-
vancing personalized medicine in can-
cer treatment is the now FDA-mandated
requirement to exclude patients with
KRAS G12 or KRAS G13 mutant colo-
rectal cancers from treatment with anti-
epidermal growth factor receptor therapy
to spare these patients from treatmentthat is ineffective or worse. With improved
development of diagnostic procedures for
noninvasive detection of KRASmutations
in stool or blood, perhaps the presence of
KRAS lesions will similarly be a marker to
exclude patients from treatment with RAF
inhibitors. Despite the conceptually dif-
ferent foundations for the application of
cytotoxic drugs versus molecularly tar-
geted therapies, the wily cancer cell con-
tinues to blur the distinction. Personalized
medicine will have to become even wilier
to successfully defeat the cancer enemy
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